Canary Islands Secures Multi Supplier Deal for Diabetes Monitoring and Insulin Pumps

Standfirst

The Servicio Canario de la Salud has awarded a framework agreement worth up to 143.8 million euros for glucose monitoring sensors and insulin infusion pumps to five suppliers, including Abbott, Air Liquide Healthcare and Senseonics. The deal will supply patients with diabetes and hypoglycaemia risk across all seven Canary Islands, though one of the original six lots is not covered in this notice.

Introduction

For people living with diabetes on Spain's Canary Islands, managing blood glucose safely often depends on a small sensor worn on the skin and, for many, an insulin pump that adjusts dosing automatically. Getting these devices to patients reliably, across an archipelago spread hundreds of kilometres apart, is a logistical and clinical challenge in its own right.

The Dirección General de Recursos Económicos del Servicio Canario de la Salud, the economic resources authority of the Canary Islands' public health service, has just closed a large framework agreement to secure that supply. The result names five different suppliers across five separate product categories, each selected through a mix of price and detailed clinical performance criteria.

Why This Contract Matters

This is a regional health procurement with a genuinely clinical backbone. Rather than buying on price alone, the health authority built award criteria around measurable clinical performance, including how accurately a sensor detects blood glucose levels and how well it identifies dangerous drops into hypoglycaemia.

The framework also covers the full range of device types patients need, from basic glucose sensors through to implantable sensors and different insulin pump configurations, some requiring a smartphone app and some designed for patients who prefer not to rely on a mobile device. This breadth reflects how varied diabetes management needs are across a real patient population.

Contract Timeline

Winners across all five lots covered in this notice were selected on 7 July 2026 and every resulting contract was concluded on 4 August 2026. The notice recording these awards was dispatched on 5 August 2026 and published in the Official Journal of the European Union on 6 August 2026, under OJ S issue 150/2026. The contracting authority has not disclosed the framework's overall duration or any renewal terms in this notice.

Contract Overview

The Servicio Canario de la Salud ran an open procedure under Directive 2014/24/EU for a framework agreement covering glucose monitoring systems and insulin infusion devices, classified mainly under CPV code 33194110, Infusion pumps, with an additional classification of 33195000, Patient monitoring system. The overall framework carries a maximum value of 143,756,790.49 EUR excluding VAT.

The procurement was structured across multiple lots, of which this notice reports results for five, numbered 1, 3, 4, 5 and 6. Lot 2 does not appear in this notice and the contracting authority has not disclosed its status. Summing the disclosed estimated values of the five lots covered here gives approximately 126.2 million euros, leaving a gap of roughly 17.6 million euros against the overall framework maximum, an amount broadly consistent with what Lot 2 alone might represent, though this is an inference rather than a figure confirmed in the notice.

Place of performance spans all seven islands of the Canary archipelago, El Hierro, Fuerteventura, Gran Canaria, La Gomera, La Palma, Lanzarote and Tenerife, reflecting the region wide reach of the Servicio Canario de la Salud.

Key Contract Details

Project Scope

Lot 1 covers basic glucose monitoring sensors, worn on the skin to continuously track blood sugar. Lot 3 covers implantable sensors, a smaller and more specialised category placed under the skin rather than attached externally. Lot 4 covers continuous insulin infusion systems using a predictive model pump, technology designed to anticipate and adjust insulin delivery based on trends in glucose readings.

Lot 5 covers continuous insulin infusion systems that require a mobile device to operate, while Lot 6 covers equivalent systems designed for patients who do not use or want a mobile device dependency. Together, these lots let the health service match device choice to individual patient circumstances, including age, digital literacy and specific clinical needs such as pregnancy or paediatric care, criteria that feature explicitly in the award scoring.

About the Contracting Authority

Dirección General de Recursos Económicos del Servicio Canario de la Salud

The Dirección General de Recursos Económicos is a regional authority responsible for economic resources within the Servicio Canario de la Salud, the public health service of the Canary Islands. Its classified activity is health and it is based in Las Palmas de Gran Canaria. It both awarded this framework and is named as the body handling review matters for the procurement.

About the Organisations Involved

ABBOTT LABORATORIES, SA and LIESNO BUNO SL

Lot 1, covering basic glucose monitoring sensors, was awarded to two separate suppliers rather than one. ABBOTT LABORATORIES, SA, based in Madrid and classified as a large enterprise, tendered a unit price of 79.99 EUR. LIESNO BUNO SL, also based in Madrid and classified as a large enterprise, tendered a unit price of 78.00 EUR. Both are recorded as winners of this lot and the notice does not explain how call offs will be divided between them, only that both hold appointed positions under the framework for this product category. Two tenders were received for this lot in total.

SENSEONICS SPAIN, S.L.

Senseonics Spain, S.L., based in Barcelona and classified as an SME, won Lot 3, covering implantable sensors, the smallest lot by value in this notice, with a unit tender price of 291.89 EUR. Only one tender was received for this lot.

AIR LIQUIDE HEALTHCARE ESPAÑA S.L.

Air Liquide Healthcare España S.L., based in Madrid and classified as a large enterprise, won Lot 4, covering predictive model insulin pump systems, with a unit tender price of 570.00 EUR. Only one tender was received for this lot.

MYLIFE DIABETES CARE S.L.U.

Mylife Diabetes Care S.L.U., based in Barcelona and classified as a large enterprise, won Lot 5, covering insulin pump systems requiring a mobile device, with a unit tender price of 500.10 EUR. Only one tender was received for this lot.

Técnicas Biofísicas S.L.

Técnicas Biofísicas S.L., based in Las Palmas de Gran Canaria and classified as an SME, won Lot 6, covering insulin pump systems that do not require a mobile device, with a unit tender price of 600.00 EUR. Only one tender was received for this lot. As a locally based Canary Islands company, its selection stands out against the mostly mainland Spanish winners on other lots.

Procurement Analysis

The award criteria in this procurement go well beyond simple price comparison. Weighting varies by lot, price carries 34 of 100 points on Lot 1, rising to 60 of 100 points on Lot 3, with the remaining points on every lot distributed across an extensive list of clinical and technical quality measures.

For the glucose sensor lots, these quality criteria include measurement accuracy expressed through a clinical metric known as MARD or mean absolute relative difference, accuracy specifically in detecting hypoglycaemia, sensor wear duration, connectivity options, allergen free materials and suitability for pregnant or paediatric patients. This level of technical detail signals that the health authority prioritised proven clinical performance and patient usability alongside cost.

Competition was thin on most lots. Only Lot 1 attracted more than one tender, with two received, while every other lot in this notice drew exactly one tender. This suggests that, for several of these specialised device categories, a small number of manufacturers realistically compete for Canary Islands health service business, a pattern common in specialised medical device markets where only a handful of firms hold the relevant clinical approvals and product range.

The framework itself uses a mixed call off structure, described as partly without reopening of competition and partly with reopening of competition. In practice, this means some purchases against the framework will follow fixed terms agreed now, while others will trigger a fresh mini competition among appointed suppliers before an order is placed, a structure that preserves some ongoing competitive pressure over the life of the agreement.

Additional Procurement Facts

None of the five lots in this notice are financed with EU funds and none are covered by the Government Procurement Agreement. No subcontracting was declared by any of the winning suppliers.

The notice lists the review organisation as the contracting authority itself, the Dirección General de Recursos Económicos del Servicio Canario de la Salud, rather than an external court or tribunal. The review deadline information recorded in the notice states a date in January 2026, which predates this notice's August 2026 publication date. This is an inconsistency the contracting authority has not clarified and it likely reflects a data carryover from an earlier stage of the procurement rather than the true current deadline for challenging this specific award.

Market and Industry Perspective

The winner list reflects the structure of the global diabetes technology market, where a mix of large multinational medical device groups, Abbott and Air Liquide Healthcare among them, compete alongside specialised diabetes technology firms such as Senseonics and Mylife Diabetes Care and smaller regional players such as Técnicas Biofísicas.

The presence of a locally based Canary Islands SME winning one of the insulin pump lots is notable in a market segment often dominated by large international manufacturers and may reflect either a genuinely competitive local offering or limited mainland competitor interest in that specific device category for this region.

Economic Significance

With a framework maximum of nearly 144 million euros, this is a substantial regional health procurement, underscoring the scale of diabetes care demand across the Canary Islands' population. Diabetes and metabolic disorders causing hypoglycaemia represent an ongoing, recurring area of public health spending and frameworks of this kind allow health systems to secure supply continuity over a multi year period rather than repeatedly re tendering individual purchases.

For the winning suppliers, appointment to this framework secures a defined revenue channel into Spain's Canary Islands health system, though actual revenue will depend on real patient volumes and the call off mechanism used for each lot.

Future Procurement Opportunities

The absence of Lot 2 from this notice is the most immediate item to watch, since its award status, whether pending, awarded separately or unresolved, is not disclosed here. Suppliers with an interest in that specific device category should monitor for a follow up notice.

Given the framework's mixed reopening of competition structure, suppliers appointed to lots with reopening provisions should also expect ongoing mini competition opportunities over the life of the agreement, rather than a single fixed award covering all future demand.

Opportunities for Suppliers

Manufacturers and distributors of diabetes technology should note the weight the health authority placed on detailed clinical and usability criteria across every lot, suggesting that future tenders in this and comparable Spanish regional health systems are likely to reward demonstrable clinical accuracy data and patient usability features rather than price alone.

The thin competition seen on four of the five lots, each drawing only one tender, may also represent an opening for other qualified manufacturers who did not participate this time, particularly once any reopening of competition rounds begin under the framework's mixed structure.

What Businesses Should Watch

Diabetes technology suppliers should watch for the resolution of Lot 2, as well as for any mini competition rounds triggered under the reopening of competition elements of this framework, since those events represent near term commercial opportunities within an already awarded structure.

It is also worth monitoring whether other Spanish regional health services adopt similarly detailed, clinically weighted award criteria for diabetes technology procurement, since this notice may represent a template other regions choose to follow.

SpainTenders.com Procurement Intelligence

This award illustrates a broader shift in how regional health systems buy medical technology for chronic disease management, moving away from price led commodity purchasing toward criteria that measure real clinical performance, such as glucose sensor accuracy and hypoglycaemia detection, alongside patient usability factors like allergen free materials and paediatric suitability.

Its strategic importance lies in how it segments the market. Rather than buying one generic glucose monitoring or insulin pump solution, the Servicio Canario de la Salud split its needs into precise clinical categories, implantable versus wearable sensors, mobile dependent versus mobile independent pumps, allowing different specialist suppliers to win the categories where they hold genuine clinical advantages rather than forcing one winner to serve every patient profile.

Suppliers can learn two things from this result. First, detailed, quantified clinical evidence appears to carry real weight in scoring, meaning manufacturers should prioritise generating and presenting rigorous accuracy and usability data ahead of future tenders. Second, thin competition on four of five lots suggests real opportunity remains for manufacturers willing to invest in Spanish regulatory approval and regional market presence, particularly in specialised categories like implantable sensors where established players currently face little direct competition.

Suppliers positioning for the still unresolved Lot 2 or for future renewal cycles of this framework, should treat the detailed criteria list disclosed here as a strong indicator of what Spanish regional health authorities are likely to prioritise in comparable future tenders.

Supplier Takeaways

• Award criteria combined price with extensive clinical and usability measures, including glucose sensor accuracy and hypoglycaemia detection performance
• Four of the five lots in this notice attracted only one tender each, pointing to limited current competition in several specialised device categories
• Lot 1 was awarded to two separate suppliers, Abbott Laboratories and Liesno Buno, indicating a multi supplier appointment structure for that category
• The framework uses a mixed call off mechanism, meaning some future purchases will require a mini competition among appointed suppliers
• Lot 2 does not appear in this notice, representing a still unresolved opportunity worth monitoring

Key Takeaways

• The Servicio Canario de la Salud has awarded a framework agreement worth up to 143,756,790.49 EUR for glucose monitoring and insulin infusion devices
• Five suppliers won across five lots covered in this notice, Abbott Laboratories, Liesno Buno, Senseonics Spain, Air Liquide Healthcare España, Mylife Diabetes Care and Técnicas Biofísicas
• The framework covers all seven Canary Islands and uses a mixed structure combining fixed terms with reopened competition for certain call offs
• None of the awarded lots are EU funded or covered by the Government Procurement Agreement and no subcontracting was declared
• Lot 2 of the original lot structure is not included in this notice and its status remains undisclosed

Conclusion

This framework agreement shows a regional health system building its diabetes technology supply chain around detailed clinical evidence rather than cost alone, splitting patient needs into precise device categories and rewarding manufacturers who can demonstrate real world accuracy and usability. For patients across the Canary Islands, it should mean access to a broader, more clinically matched range of monitoring and insulin delivery technology.

For the winning suppliers, from global names like Abbott to the locally based Técnicas Biofísicas, it secures a multi year foothold in a health system serving a geographically dispersed island population. With Lot 2 still unaccounted for and reopening of competition mechanisms built into the framework, this is likely not the final chapter in how the Canary Islands source this technology.

Source: Tenders Electronic Daily (TED), Contract Award Notice 544051-2026, Official Journal of the European Union, OJ S issue 150/2026, published on 06/08/2026.